HGH Fragment 176-191 vs CJC-1295 (no DAC)

A detailed side-by-side comparison of HGH Fragment 176-191 and CJC-1295 (no DAC) covering dosing, storage, research findings, and practical usage.

Overview

HGH Fragment 176-191: The lipolytic fragment of human growth hormone (amino acids 176-191), targeting fat metabolism without the growth-promoting or diabetogenic effects of full-length HGH.

CJC-1295 (no DAC): A GHRH analog that stimulates growth hormone release without the Drug Affinity Complex.

Comparison Table

HGH Fragment 176-191 Research

HGH Fragment 176-191 is a synthetic peptide corresponding to the C-terminal portion (amino acids 176-191) of human growth hormone. Research published in journals including Endocrinology and Obesity Research has demonstrated that this specific fragment retains the lipolytic (fat-burning) activity of full-length HGH while lacking the growth-promoting and diabetogenic effects. In vitro studies show it stimulates lipolysis and inhibits lipogenesis in adipose tissue. Animal studies have demonstrated significant reductions in body fat without changes in IGF-1 levels, blood glucose, or insulin sensitivity — a key advantage over exogenous HGH. The fragment works by mimicking the way natural growth hormone regulates fat metabolism, specifically through beta-3 adrenergic receptor pathways. AOD-9604, a closely related peptide with an additional tyrosine residue, reached Phase 2b clinical trials for obesity. HGH Frag 176-191 remains an active area of research for targeted fat reduction without systemic growth hormone effects.

HGH Fragment 176-191 Full Guide | CJC-1295 (no DAC) Full Guide | Dosage Calculator | Browse Peptides

For laboratory research use only. Not for human consumption.